Related Experiment Video
Updated: Feb 20, 2026
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
Design of potent B-RafV600E inhibitors by multiple copy simulation search strategy
Ze-Feng Wang1, Peng-Fei Wang1, Jun-Ting Ma1
1State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing, China.
Abstract:
B-Raf kinase is a vital intermedium in the mitogen-activated protein kinase (MAPK) signaling pathway, which transforms extracellular signals into cellular mechanisms. Mutations in this kinase, for instance, the most common V600E mutation, can lead to the ERK signaling pathologically activated and hence cause severe diseases such as somatic tumors. So far, the development of B-Raf inhibitors has made remarkable progress. However, the resistance and relapse of approved Raf drugs have been widely reported, and the optimization for old drugs and the discovery for new inhibitors still remain a significant task. In this study, we designed and evaluated a series of novel B-RafV600E inhibitors. A fragment library has been established before the docking simulation carried out using the MCSS strategy (multicopy simulation search). The appropriate fragments were reassembled to provide new candidate compounds, which were further screened by iterative docking simulations and molecular dynamics. Bioassays were carried out to evaluate the pharmacological profile of the compounds identified and synthesized. The result showed that compound 5n had an impressive enzyme inhibitory and antiproliferation activity, suggesting a promising potential in the future study.
Insights
Researchers developed new B-Raf inhibitors to combat cancer drug resistance. Compound 5n demonstrated significant enzyme inhibition and antiproliferation activity, offering potential for future cancer therapy development.
Area of Science:
- Biochemistry and Molecular Biology
- Medicinal Chemistry
- Cancer Biology
Background:
- B-Raf kinase is a key component of the MAPK signaling pathway, crucial for cellular functions.
- Mutations like B-Raf V600E lead to aberrant ERK signaling, driving diseases such as somatic tumors.
- Existing B-Raf inhibitors face challenges with drug resistance and relapse, necessitating new therapeutic strategies.
Purpose of the Study:
- To design and evaluate novel inhibitors targeting the B-Raf V600E mutation.
- To identify potent compounds with improved pharmacological profiles for cancer treatment.
- To address the unmet need for effective B-Raf inhibitors overcoming resistance mechanisms.
Main Methods:
- Utilized a fragment library and multicopy simulation search (MCSS) for initial docking.
- Employed iterative docking simulations and molecular dynamics for candidate compound screening.
- Conducted bioassays to assess enzyme inhibition and antiproliferation activity of synthesized compounds.
Main Results:
- Compound 5n exhibited significant B-Raf V600E enzyme inhibitory activity.
- Compound 5n demonstrated potent antiproliferation effects in relevant cellular models.
- The study successfully identified and validated a novel B-Raf inhibitor candidate.
Conclusions:
- Compound 5n shows promising potential as a therapeutic agent against B-Raf V600E-driven cancers.
- The designed inhibitors represent a significant advancement in addressing drug resistance in B-Raf targeted therapies.
- Further investigation of compound 5n is warranted for clinical development.
More Related Videos
13:34A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
10:29Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
